Xeris Biopharma HoldingsXERS -3.30%71 Days Payable is 62.75 as of Mar. 2026, which is 62% below its 10-year median of 165.00. GuruFocus rates XERS with a GF Score™ of 71/100 and a GF Value™ of $5.19 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 927 Drug Manufacturers companies, Xeris Biopharma Holdings ranks worse than 67.64% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Xeris Biopharma Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xeris Biopharma Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Xeris Biopharma Holdings's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings (XERS) has a Days Payable of 62.75 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Xeris Biopharma Holdings and its competitors. This is 62% below median its historical median of 165.00. Over the past decade, Xeris Biopharma Holdings' Days Payable has ranged from 23.00 to 150,151.88. According to the industry distribution chart, Xeris Biopharma Holdings ranks #627 out of 927 companies in the Drug Manufacturers industry, placing it in the top 67.6%.
Is Xeris Biopharma Holdings' Days Payable too high?
Xeris Biopharma Holdings' current Days Payable of 62.75 is 62% below median its 10-year median of 165.00. Over the past 10 years, this metric has ranged from a low of 23.00 to a high of 150,151.88. The Drug Manufacturers industry median Days Payable is 90.38. Xeris Biopharma Holdings' value of 62.75 is 30.6% below this industry median. Based on the distribution chart, Xeris Biopharma Holdings ranks #627 out of 927 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Xeris Biopharma Holdings has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Days Payable compare to PAHC and PRGO?
According to the Drug Manufacturers industry distribution chart, Xeris Biopharma Holdings ranks #627 out of 927 companies for Days Payable. This places Xeris Biopharma Holdings in the lower half of its industry. The industry median Days Payable is 90.38. Xeris Biopharma Holdings' value of 62.75 is 30.6% below this benchmark. Historically, Xeris Biopharma Holdings' own Days Payable has ranged from 23.00 to 150,151.88 over the past decade. While the company's 10-year median is 165.00 vs. the industry median of 90.38, Xeris Biopharma Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xeris Biopharma Holdings's current Days Payable of 62.75 is 30.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Xeris Biopharma Holdings and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeris Biopharma Holdings's current Days Payable is 62.75, which is 62% below median its own 10-year median of 165.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (XERS) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.19, compared to a current price of $8.35 — trading 60.9% above its estimated fair value. The current Days Payable is 62.75, which is 62% below median its 10-year median of 165.00 and 30.6% below the Drug Manufacturers industry median of 90.38. Xeris Biopharma Holdings' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Xeris Biopharma Holdings (XERS), the current Days Payable is 62.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xeris Biopharma Holdings (XERS) Overvalued in 2026?
Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued.
The current stock price of $8.35 is trading 60.9% above its estimated GF Value™ of $5.19.
GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.
Key valuation signals for XERS:
Days Payable: 62.75 (62% below median its 10-year median of 165.00)
GF Value™: $5.19 vs. price of $8.35 (60.9% above fair value)
Industry Position: 30.6% below the Drug Manufacturers median (#627 of 927)
No single metric tells the full story. See the XERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
71GF Score
Get the complete analysis for XERS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XERS has been successfully added to your 
